Pancreatic cancer | Guidance and guideline topic | NICE

9 new

and

0 updated

products since January 2017.

NICE Pathways - mapping our guidance

Interventional procedures guidance

Irreversible electroporation for treating pancreatic cancer (IPG579) May 2017
Autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy (IPG274) September 2008
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma (IPG464) September 2013
Laparoscopic distal pancreatectomy (IPG204) January 2007

NICE Medtech innovation briefings

Cellvizio confocal endomicroscopy system for characterising pancreatic cysts (MIB69) June 2016

Technology appraisal guidance

Quality standards

Suspected cancer (QS124) June 2016

NICE Guidelines

Suspected cancer: recognition and referral (NG12) June 2015

In development

Gastroenteropancreatic tumours (unresectable, metastatic, non-progressive) - lanreotide (subcutaneous injection) [ID961] (GID-TA10026) TBC Technology appraisal guidance
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer [ID1058] (GID-TA10116) November 2017 Technology appraisal guidance
Pancreatic cancer - capecitabine [ID389] (GID-TAG394) TBC Technology appraisal guidance
Pancreatic cancer (locally advanced, metastatic) - masitinib [ID566] (GID-TAG330) TBC Technology appraisal guidance
Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513] (GID-TAG363) TBC Technology appraisal guidance
Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658] (GID-TAG494) TBC Technology appraisal guidance
Pancreatic cancer: diagnosis and management in adults (GID-CGWAVE0802) January 2018 NICE guidelines